Overview

Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases

Status:
Recruiting
Trial end date:
2023-07-28
Target enrollment:
Participant gender:
Summary
Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain Metastases
Phase:
Phase 2
Details
Lead Sponsor:
Medical University of Vienna
Collaborator:
Daiichi Sankyo, Inc.
Treatments:
Trastuzumab